Eight year experience with the CarboMedics bileaflet valvular prosthesis

Two hundred and two patients (97 female and 105 male; mean age: 45. 5+/-9 years) received CarboMedics bileaflet valves during a period of eight years. Ninety-one patients received mitral, 72 aortic and 39 aortic+mitral valve prosthesis. Tricuspid plasty and coronary artery bypass surgery were the co...

Full description

Saved in:
Bibliographic Details
Published inAnnals of thoracic and cardiovascular surgery Vol. 5; no. 6; p. 382
Main Authors Sinci, V, Halit, V, Kalaycioglu, S, Gunaydin, S, Imren, Y, Gokgoz, L, Soncul, H, Eesoz, A
Format Journal Article
LanguageEnglish
Published Japan 01.12.1999
Subjects
Actuarial Analysis
Adolescent
Adult
Aged
Analysis of Variance
Aortic Valve - surgery
Cardiac Output, Low - etiology
Cause of Death
Coronary Artery Bypass
Female
Follow-Up Studies
Heart Valve Prosthesis - adverse effects
Heart Valve Prosthesis Implantation - adverse effects
Humans
Incidence
Male
Middle Aged
Mitral Valve - surgery
Postoperative Hemorrhage - etiology
Prosthesis Design
Survival Rate
Thromboembolism - etiology
Tricuspid Valve - surgery
Online AccessGet more information

Cover

More Information
Summary:Two hundred and two patients (97 female and 105 male; mean age: 45. 5+/-9 years) received CarboMedics bileaflet valves during a period of eight years. Ninety-one patients received mitral, 72 aortic and 39 aortic+mitral valve prosthesis. Tricuspid plasty and coronary artery bypass surgery were the concomitant operations in 17 and 12 patients, respectively. The mean follow-up period was 24.7 months and the ratio was 91%. Overall operative mortality was 3.96% (8 patients); 2.78% for aortic valve replacement (AVR), 3.29% for mitral valve replacement (MVR) and 7.7% for double valve replacement (DVR). The late mortality rate was 2.89% for AVR, 2.2% for MVR and 8. 3% for DVR. The main cause of mortality was low cardiac output. The overall survival rate was 91.5% in 2 years. The actuarial freedom from thromboembolism in 2 years was 97% for AVR, 95% for MVR and 84% for DVR. No mortality due to heamorrhagic events was observed. CarboMedics prosthetic heart valves may be used satisfactorily with a low incidence of valve-related morbidity and mortality.
ISSN:1341-1098